Nav: Home

Review suggests metformin associated with small height increase in children

September 28, 2015

A review of the medical literature suggests the diabetes medication metformin may be associated with a small increase in height in children and adolescents in randomized clinical trials providing the largest cumulative metformin doses, according to an article published online by JAMA Pediatrics.

There has been increasing off-label use of metformin in children and adolescents, often as part of the management of polycystic ovary syndrome, but also for impaired glucose tolerance, nonalcoholic fatty liver disease and obesity.

Normand G. Boulé, Ph.D., of the University of Alberta, Canada, and coauthors included 10 studies with a total of 562 children and adolescents at baseline; 59 percent were female (n=330); the average age within the studies ranged from nearly 8 to 16; and the average body mass index (BMI) ranged from 18.4 to 41. Participants used metformin from three to 48 months.

Overall, height changes were not significantly different between metformin users and control group participants in the studies, the authors report. However, further analyses stratified according to the cumulative metformin dose (in milligrams per day times the number of days of treatment) showed about a one-centimeter increase in height with metformin use in the five studies providing the largest cumulative metformin doses but not in the five studies providing the lowest doses compared with the control group.

The authors note limitations to their study, which include their inability to obtain height data from many studies, even though this information had been collected for the reporting of BMI.

"While an approximate 1-cm increase in height may appear small, it is likely underestimated given that many studies were of short duration and included older adolescents, potentially after epiphyseal growth plate closure. ... Our results also suggest a need for additional longer-term studies in younger participants because preliminary evidence suggests that these individuals may experience greater increases in height compared with a control group," the study concludes.
-end-
(JAMA Pediatr. Published online September 28, 2015. doi:10.1001/jamapediatrics.2015.2186. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: Please see article for additional information, including other authors, author contributions and affiliations, etc.

Media Advisory: To contact corresponding author Normand G. Boulé, Ph.D., call Jocelyn Love at 780-492-8804 or email jocelyn.love@ualberta.ca.

To place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/jamapediatrics.2015.2186

The JAMA Network Journals

Related Metformin Articles:

Diabetes drug study explores cardiovascular risks for patients with kidney disease
Among the 30 million U.S. adults with Type 2 diabetes, 20% have impaired kidney function.
LSU Health research targets metformin as breast cancer prescription
Research conducted by Suresh Alahari, PhD, Professor of Biochemistry and Genetics at LSU Health New Orleans School of Medicine, has found that metformin, a commonly prescribed drug for Type 2 Diabetes, may be effective in treating cancers that lack a protein called Nischarin.
Comparing major adverse cardiovascular events among patients with diabetes, reduced kidney function treated with metformin or sulfonylurea
This observational study compared major cardiovascular events (including hospitalization for heart attack, stroke, transient ischemic attack or cardiovascular death) among patients with diabetes and reduced kidney function treated with metformin or a sulfonylurea (a class of drugs to treat diabetes).
New insights into how diet & medication impact the influence of gut bacteria on our health
Research published in Cell on 29th August by the groups of Filipe Cabreiro from the MRC London Institute of Medical Sciences and Imperial College and Christoph Kaleta from Kiel University in Germany has demonstrated that diet can alter the effectiveness of a type-2 diabetes drug via its action on gut bacteria.
Metformin could lower risk of dementia in African Americans with type 2 diabetes
A large observational cohort study examining male veterans aged over 50 years with type 2 diabetes found that metformin use was associated with a significantly lower risk of dementia in African American patients.
More Metformin News and Metformin Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...